Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Two clinical statements (high triglycerides treatment; CV risk reduction) align with the label, but most other claims concern retail pricing, discount programs (manufacturer, CVS/Walgreens, % reductions), eligibility rules, and application methods that are not supported by the provided FDA label excerpts. Several program-related numeric/cost and retailer-specific assertions cannot be verified against the supplied prescribing information.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl.
Label excerpts identify VASCEPA (icosapent ethyl) as the drug product.
Vascepa is used to treat high triglyceride levels.
Indications include adjunct to diet to reduce TG levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia.
Vascepa is used to reduce the risk of cardiovascular events in patients with high triglycerides.
Indications include adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG levels (≥ 150 mg/dL) with established CVD or diabetes plus additional risk factors.
Unsupported Statements
The average retail price of Vascepa in the United States is around $1,200 per month for a 30-day supply.
No pricing/retail cost information is present in the provided label excerpts.
Vascepa assistance programs are designed to help patients access Vascepa at a lower cost.
The provided FDA label excerpts do not describe or authorize assistance program design or purpose.
Vascepa assistance programs can reduce the out-of-pocket cost of Vascepa by up to 90%.
No out-of-pocket reduction amounts are stated in the provided label excerpts.
Patient Assistance Programs (PAPs) are offered by the manufacturer of Vascepa, Amarin Pharmaceuticals.
The provided FDA label excerpts do not mention PAPs or manufacturer-administered assistance programs.
PAPs can provide free or reduced-cost Vascepa to eligible patients.
No PAP availability or terms are stated in the provided label excerpts.
Amarin Pharmaceuticals offers discounts on Vascepa for patients who are not eligible for PAPs.
No manufacturer discount program language is present in the provided label excerpts.
CVS Pharmacy offers discounts on Vascepa for patients who are not eligible for PAPs.
No pharmacy/retailer-specific discount program information is present in the provided label excerpts.
CVS Pharmacy offers a 10% discount on Vascepa for patients who are not eligible for PAPs.
No numeric retailer discount information is present in the provided label excerpts.
Walgreens offers discounts on Vascepa for patients who are not eligible for PAPs.
No pharmacy/retailer-specific discount program information is present in the provided label excerpts.
Walgreens offers a 5% discount on Vascepa for patients who are not eligible for PAPs.
No numeric retailer discount information is present in the provided label excerpts.
Patients eligible for government assistance programs such as Medicaid or Medicare may be able to access Vascepa at a lower cost.
No government program eligibility/cost language is present in the provided label excerpts.
The average cost of Vascepa with assistance is around $120 per month for a 30-day supply.
No cost benchmarks or assistance pricing are stated in the provided label excerpts.
The Amarin Pharmaceuticals PAP provides free Vascepa to eligible patients.
No PAP terms (free/reduced cost) are stated in the provided label excerpts.
Patients must have a certain income level to be eligible for PAPs.
No PAP eligibility criteria are described in the provided label excerpts.
Patients must have certain types of insurance to be eligible for PAPs.
No PAP eligibility criteria are described in the provided label excerpts.
Patients must have a certain medical condition to be eligible for PAPs.
No PAP eligibility criteria are described in the provided label excerpts.
Vascepa assistance programs can reduce the out-of-pocket cost of Vascepa for patients.
No assistance programs or out-of-pocket cost reduction are described in the provided label excerpts.
Vascepa assistance programs can increase access to Vascepa for patients who are struggling to afford it.
No statements about access effects are described in the provided label excerpts.
Vascepa assistance programs can improve health outcomes for patients by making Vascepa more affordable.
The provided label excerpts do not discuss assistance programs’ impact on outcomes.
Income requirements are a limitation of Vascepa assistance programs.
No assistance program structure/limitations are described in the provided label excerpts.
Insurance requirements are a limitation of Vascepa assistance programs.
No assistance program structure/limitations are described in the provided label excerpts.
Medical requirements are a limitation of Vascepa assistance programs.
No assistance program structure/limitations are described in the provided label excerpts.
Patients can apply for Vascepa assistance programs through the manufacturer's website or by contacting their pharmacy.
No application process for assistance programs is described in the provided label excerpts.
Patients can visit the Amarin Pharmaceuticals website to apply for PAPs.
No PAP application instructions or website references are described in the provided label excerpts.
Patients will need to complete an application to be eligible for PAPs.
No PAP application requirement is described in the provided label excerpts.
Vascepa assistance programs can reduce the out-of-pocket cost of Vascepa by up to 90%.
No assistance program cost reduction percentages are stated in the provided label excerpts.
Patients can apply for Vascepa assistance programs through the manufacturer's website or by contacting their pharmacy.
No application process for assistance programs is described in the provided label excerpts.
Vascepa assistance programs can increase access to Vascepa for patients who are struggling to afford it.
No statements about access effects are described in the provided label excerpts.
Contradictions
Important Omissions
No dosing/administration details were evaluated against the label; the provided claims do not include any label-relevant dosage instructions (e.g., 4 g/day with food; capsule swallowing whole).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the clinical indication statements roughly align with the label, the majority of claims are about pricing/assistance programs that are not supported by the provided FDA label excerpts. If relied upon, unsupported cost/eligibility assertions could mislead access planning; however, no contraindication/warning/safety misinformation was asserted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims concern patient assistance pricing, eligibility criteria, retailer/manufacturer discounts, and application methods that are not present in the provided FDA prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported content (indications, limitations of use, dosage/administration, contraindications, and label-described risks). Remove or qualify assistance-program pricing/percent/eligibility and retailer-specific discount assertions unless supported by the FDA label text provided.